The real-life efficacy and safety of secukinumab therapy (150 and 300 mg) in patients with moderate-to-severe plaque psoriasis: A twelve week, single center, retrospective study

• Huvudskapare: İncilay Kalay Yıldızhan (Författare, medförfattare), Merve Aygün (Författare, medförfattare), Nihal Kundakçı (Författare, medförfattare)
• Materialtyp: Bok
• Publicerad: Galenos Publishing House, 2021-09-01T00:00:00Z.
• Ämnen: article
• Länkar: Connect to this object online.

Background and Design: Secukinumab is an effective treatment option in moderate-to-severe plaque type psoriasis. However, there are a few real-life data studies comparing the efficacy of 150 mg and 300 mg dosages. The aim of this study was to evaluate the efficacy and safety of secukinumab at 150 mg...